Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)
Sponsor: NS Pharma, Inc.
This PHASE4 trial investigates Duchenne Muscular Dystrophy and is currently ongoing. NS Pharma, Inc. leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE4
-
Nov 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE4
Status: Enrolling By Invitation → Active Not Recruiting
-
Dec 2021 — Nov 2022 [monthly]
Enrolling By Invitation PHASE4
Status: Recruiting → Enrolling By Invitation
-
Sep 2021 — Dec 2021 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
May 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- NS Pharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .